The glucose-insulin system is a challenging process to model due to the feedback mechanisms present, hence the implementation of a model-based approach to the system is an on-going and challenging research area. A new approach is proposed here which provides an effective way of characterising glycaemic regulation. The resulting model is built on the premise that there are three phases of insulin secretion, similar to those seen in a proportional-integral-derivative (PID) type controller used in engineering control problems. The model relates these three phases to a biological understanding of the system, as well as the logical premise that the homeostatic mechanisms will maintain very tight control of the system. It includes states for insulin, glucose, insulin action and a state to simulate an integral function of glucose.
Introduction
Over recent decades much research has been devoted to the development of models that characterise the interaction between glucose and insulin. Probably the most widely known, accepted and applied model in this field is the Minimal Model (and its variants) introduced by Bergman et al. [1] . Previously, models had been large and very complex in structure, whereas the Minimal Model is, as the name suggests, minimal in terms of its structure and the number of key system parameters that it includes. In particular, the Minimal Model also includes in its structure a very important parameter representing insulin sensitivity, which is a measure of how much glucose is removed from the blood per unit of insulin. In certain situations the Minimal Model is a very useful tool, however in others it does not necessarily meet expectations as shown by
De Gaetano et al. [2] . For example, insulin secretion with the minimal model is stopped after the glucose level falls below a certain threshold, making it invalid once the system has returned to a steady state.
More recently, a Beta Cell Mass Model has been developed by Topp et al. [3] .
Unlike the Minimal Model, it is concerned with a long-term view of glucoseinsulin dynamics and includes an additional compartment to represent β-cell mass. While this model appears to predict long-term aspects of the system and disease progression well, it lacks a representation of insulin delay and insulin secretion is geared to a steady state, which makes it far less useful for short-term modelling. Jauslin/Silber [4] have also developed an alternative model to characterise glucoseinsulin interaction. The Jauslin/Silber model follows standard pharmacokinetic structures and attempts to be applicable to both Oral Glucose Tolerance Tests (OGTTs) and Intravenous Glucose Tolerance Tests (IVGTTs) in both healthy and type 2 diabetic patients. Using this model and the data collected to look at 24 hour profiles of these subjects, aspects of the insulin effect compartment have been incorporated into the design of the model presented here.
The glucose-insulin homeostatic system is an important control mechanism in both animals and man. If the glucose level is elevated above normal (hyperglycaemia), its toxic effect can damage blood vessels, nerves and other important body systems. When the blood glucose level is raised, the endothelial cells that line the blood vessels absorb more glucose than normal, leading the blood vessels to grow thicker and weaker which reduces blood flow throughout the body. This can cause retinopathy leading to vision loss, neuropathy (loss of sensation) and, in severe cases, amputation is necessary. Other potential complications include nephropathy, which may require dialysis or kidney transplant, heart attacks, strokes and muscle wasting. If the glucose level falls too low (hypoglycaemia), there is insufficient energy to sustain normal function of the central nervous system, which may result in coma and even death. For a full review of the eitology of type 2 diabetes see Haffner [5] .
To prevent serious damage such as that detailed above, the glucose-insulin homeostatic system is crucial and is therefore normally very finely controlled. It is critically damped or even very slightly over-damped, keeping it close to a steady state or a fixed point with little overshoot and returning high levels of glucose rapidly back to the fixed point show by Bolie [6] .
The Model

Modelling Approach
The aim of the modelling approach undertaken here was to create a unified, robust model for the glucose-insulin system that would:
• Be applicable to a variety of different clinical tests, such as an IVGTT and hyperglycaemic or euglycaemic clamps.
• Be stable, robust (e.g. not having an output which increases exponentially over time) and ensure that meaningful results would be produced even with large variations between subjects.
• Give realistic results, even with extremes of data, such as high insulin resistance in cases where the subject is progressing towards type 2 dia-betes or in an animal model such as a Zucker rat model shown in [7] .
Another example would be high fasted glucose levels where a subject has uncontrolled type 2 diabetes.
It is desirable to have a model that is minimal in form, but it must still contain sufficient structural parameters to accurately model the physical system. It must therefore contain only necessary components and have only one set of parameters per individual, but provide enough flexibility to explain variation between subjects. In order to ensure that the model remains valid in extreme situations, it should adhere to biological theory in such a way that parameter difference between subjects represents different physical attributes. The model should use familiar concepts so it is easily understood and can be applied by both the mathematical/engineering community and the pre-clinical and clinical bioscience community.
Model Concept
Various engineering disciplines require a very fine level of control to be maintained over systems -chemical synthesis processes, for example, may require fine control over water temperature. Control could be achieved using a thermostat, where a heater is switched on or off depending on the water temperature, however this would not give sufficiently accurate control for some situations, such as distilling in [8] , so engineers have developed more accurate controllers specifically for this task. The human body requires similar levels of fine control for its homeostatic mechanisms. It is a logical conclusion that both human design and the process of evolution may have developed an appropriate solution in the form of a similar controller.
A PID controller has been used in many engineering applications, see for example [9] . It consists of three terms to control the system output. In a normal PID controller, a configured set-point is compared to the output of the system. The difference between these is the error signal. The PID controller uses this error signal to try and make the system return to the set-point, where the error signal would be zero. The PID controller produces three control signals:
proportional, which is a multiple of the error signal, integral, the area under the curve of the error signal, and differential, the rate of change of the error signal.
A PID controller has also been used as a method of controlling glucose levels in type 1 diabetics, i.e. those diabetics who do not secrete any insulin. There have been attempts to produce an artifical pancreas using continous glucose monitors with a PID controller to regulate the infusion of insulin [10, 11, 12, 13, 14, 15] .
To the authors' knowledge, there has been no attempt to use a PID controller as an analogy for β-cells in an attempt to explain how they function. The controller can be shown to fit with the way that the beta cells in the pancreas secrete insulin:
Proportional:
• In mathematical terms, this means that for every unit of plasma glucose, a fixed amount of insulin is released by the pancreas. See Figure 3 .
• This part of the controller simulates the secretion in basal conditions. The proportional aspect maintains a basal level of glucose in the system and a basal level of insulin to match.
• In biological terms, this means that glucose enters the beta cell which, via glycolysis and oxidative phosphorylation, increases the level of ATP [16] .
In the proportional controller analogy, the ATP predominantly promotes granules of pro-insulin towards the membrane. See Figure 1 .
Integral:
• In mathematical terms, this is the area under the curve (AUC) of the glucose concentration.
• This part simulates the second phase insulin response: the shoulder of insulin observed after an IVGTT.
• In biological terms, this is similar to the proportional control and means that an accumulation of glucose causes the beta cells to secrete an additional quantity of insulin, possibly from the readily releasable pool [17] .
This represents the amount of insulin required to remove the glucose after a meal, sugar intake or clinical challenge.
Derivative:
• In mathematical terms, this is the rate of change of glucose level.
• This part represents the first phase insulin response: the relatively high amount of insulin that is seen initially in experiments such as IVGTT.
• In biological terms, this could mean that the docked insulin granules on the cell membrane are predominantly released in a rapid response to a large increase in the amount of glucose present. It gives a measured response to sudden, large changes in concentration of glucose but has little effect when levels rise slowly.
<< Figure 1 in here >>
The model presented here is split into three sections: Insulin Secretion (I ( t) and I i (t)), Delayed Insulin Action (I a (t)), and Net Difference in Glucose G(t)).
Insulin Secretion
The basal levels of glucose and insulin are not fixed points in the biological mechanism. Instead, they are determined by the effect they have on each other in their steady states. The Beta Cell Mass Model [3] has been developed in this way; the basal levels of each are not defined, but are determined by the combination of parameters used. The model shows what can happen in the system if a reduction of insulin sensitivity occurs. This is a central point for model design as it is vital in ensuring that the parameters have relevance to the underlying biology. A classic PID controller could be related to a biological system by saying the set point was the basal glucose level and the error signal was the basal level minus the current level. Although having a set point for basal levels of glucose would produce similar results, it would not be a mechanistic representation of the underlying biology. In reality, this is not quite a valid analogy as a biological system does not have a defined set point, so the challenge is to design a model with similar terms to those present in a PID Controller without a set point.
The terms in the PID controller relate to the biological process as follows:
This term simply creates the basal level under static conditions. The proportional secretion rate is produced by taking the level present in the glucose compartment.
Integral:
This is non-trivial as the area under the glucose curve will increase over time, causing the system to become unstable. Hence the integral function must decay over time when the system tends towards steady state. It is created by taking the concentration in the glucose compartment as the rate of change of a virtual
Derivative:
This is a rate of change, so the absolute value of the glucose does not matter. This is simply taken as the rate of change of glucose, and is incorporated in the following equation:
Delayed Insulin Action
There is a delay between insulin secretion and its action lowering glucose.
There are several sources that state that this delay could be caused by factors including, but not limited to, interstitial action sites and saturation of certain pathways [18, 19, 20] . This delay has been incorporated into other models and is well-validated [1, 4] The duration of the delay is relatively short in clinical terms (of the order of a few minutes), however compared to the time-scales considered in this model it is significant and therefore important to include.
In the tests shown below, the IVGTT and the hyperglycaemic clamp both start with an elevated level of glucose. As insulin and glucose are both drivers of glucose disposal rate, as illustrated by equation 4, it is difficult to distinguish whether the high glucose disposal rate is due to the elevated glucose level, the corresponding elevated insulin level or both. Therefore, from the tests below, it is difficult to establish whether a delay in insulin action is present; however, based on evidence from the literature that a delay should be present, it has been decided that a delay should be incorporated into the model.
In order to include this delay in the model, an insulin action compartment, I a (t), was incorporated. This compartment is the same as the interstitial compartment in the Minimal Model, but is rearranged here for easy interpretation ofthe parameters:
where k iar is the clearance rate from the insulin action compartment.
Net Difference in Glucose
The glucose compartment has a number of inputs (which are impossible to determine without tracer experiments, [21] ) and a number of outputs. The relative rates of supply and dispersal of glucose in this compartment determine the basal level. This is modelled in a clear manner in the Beta Cell Mass Model [3] ; it has an appearance rate that is made up of all unknown appearance rates and all the disposal rates that can be calculated. The appearance rate cannot be established without tracer experiments, however as appearance rate is related to the amount of glucose present, obtaining an absolute value is unimportant.
Insulin has an effect on both the production rate of glucose and its disposal rate, however it is impossible to distinguish and quantify the effect on each as the end result is the same.
This provides us with three key parameters (shown in equation (4)):
• Rate of glucose production (which is fixed), g p .
• Glucose Effectiveness, which describes the insulin-independent removal of glucose (i.e. the removal of glucose based on glucose concentration alone), g r .
• Insulin Sensitivity, which is the net effect of insulin on lowering the glucose level, k si .
Figure (2) 
Steady States
As mentioned above, unlike some previous models this system does not have steady states dependent on parameters such as glucose and insulin basal levels.
The system should tend to steady states based on the system parameters and the feedback components present.
At steady state, nothing is changing hence the derivative term in the model is zero. With a classic PID controller, there is an error signal entering the controller; however this is not the case with this system as there is no "set point"
to derive an error signal from. The integral control is therefore required to introduce decay. This makes the calculations slightly complex as the steady state for this parameter is non-zero.
From the system equations (1)- (4) the steady states can be calculated algebraically, for example from equation (1) we have:
Adding in the proportional control, the steady state for insulin becomes:
From equation 3 the steady state for insulin action is given by:
and the resulting steady state for glucose is given by:
These can be calculated from the system equations algebraically.
Structural Identifiability
The problem with using a simplistic model, such as a 2-compartment model, is that it does not capture all the dynamics of the system -such as the variable insulin dynamics created by rapid changes in glucose [22] -and hence is not an accurate representation. On the other hand, a pathway model would require a larger number of parameters which would allow different combinations of values to produce the same system output. As a variety of different parameter combinations could be used to fit the same data, it would be impossible to tell which was actually correct; this would make it impossible to validate the model and therefore render it practically useless. The solution is to create a model which is a balance between these two approaches, by using not only parameters that can be uniquely identified but also a mechanistic structure that adequately describes the physical process and dynamics that are observed. This creates a need for a test to validate the model by ensuring that all parameters can be uniquely identified.
Such a test exists in the form of structural identifiability analysis. A system is said to be structurally globally identifiable if, with infinite, noise-free observations, there is only one possible set of parameters that can produce the output. Although real data will be neither infinite nor noise-free, structural identifiability in this form is a step on the way to approaching numerical identifiability or parameter estimation with greater confidence. Glucose and insulin measurements can be taken for this model. The insulin integral compartment is just a representation of an integral function. The model was treated as an uncontrolled non-linear system. All the parameters including initial conditions were considered unknown. There are various techniques for performing a structural identifiability analysis, [23] . The Lie-symmetry approach by Yates et al. [24] has been applied to the model introduced here, as other techniques such as the Taylor series approach could not yield a solution due to computational difficulties. The analysis is presented in the appendix and was performed using Mathematica 7 [25] . Mathematica was selected for the analysis as it is excellent for complex symbolic manipulation and performing the analysis by hand would be time-consuming and error-prone. System Observability is a prerequisite for the Lie-symmetry technique, so the Observability Rank Criterion was applied to the model with observations of G(t) and I(t), which showed it to be observable.
Application of this approach concluded that the model is at least locally identifiable (as global identifiability cannot be established with the Lie-symmetry approach) when two parameters were known: g p , which represents glucose production, and k p , the proportional insulin secretion function; other insulin secretion terms could be used instead, however it is easier to consider the proportional control as it can be calculated at basal states.
This leads to issues with the following parameters:
g p -This represents the amount of glucose entering the system, which is typically unknown. It can be set to an estimate, perhaps obtained from a tracer experiment, as the clearance is fractional so an exact value is not necessary.
k p -The proportional insulin secretion function is more difficult to estimate, however assuming that that the integral component is negligible at steady state a rough estimate for k p can be obtained using the known insulin clearance with this expression which has been derived from the steady state.
Parameter Estimation
The data used for parameter estimation were rat data (IVGTT and hyperglycaemic clamps) from AstraZeneca and data obtained from an IVGTT experiment on a healthy human and previously used with the Minimal Model and the program MINMOD by [26] . The data were fitted using acslX 2.5 [27] and a PKPD toolkit developed at AstraZeneca. Fitting was performed using a Table 2 for the fitted parameters. The description of the parameters is in Table   1 . << Table 1 in here>> << Table 2 The insulin sensitivity (k si ) and glucose removal rate (g r ) are clearly defined, making it easy to identify the difference between subjects.
This paper introduces a new concept for the glucose-insulin model, in particular the PID approach to insulin secretion terms. Other models have included insulin secretion terms; for example the Minimal Model [1] , although this does not have a first-phase insulin secretion term, and the DIST and DISTq models [28, 29] , though these use larger numbers of parameters than the model presented here.
Insulin sensitivity in this model was based on the interstitial insulin compartment from the Minimal Model, however there are valid alternative methods to calculate insulin sensivity [30] .
Unlike many other models, this model was not developed for a specific test, such as IVGTT, or hyperglycaemic clamp, and was designed to be a fully-coupled system to ensure it was physiologically representative of the glucose-insulin feedback system. This should ensure its applicability in a variety of circumstances and attempts at applying this model to tests such as OGTT (Oral Glucose Tolerance Test) and diurnal variation due to feeds are currently being investigated.
There are other factors affecting the system which could be taken into account in the modelling. Insulin clearance is known to affect different situations such as OGTTs, IVGTTs and fasted conditions seen by [31] ; including a C-peptide model [32] would help to solve this problem. Incretins and lipids, which also play a role in insulin secretion, are not taken into account in this model. Additionally, disease modelling -such as depletion of insulin capacity -is not taken into account here, however it may help quantify certain aspects of disease where other models may fail. For instance, if the first phase of insulin secretion was decreased, this would be reflected in the derivative parameter (k d ). These are all factors that are to be included in future work and development of the model.
Models and control systems for managing glucose homeostatics are becoming increasingly important with current developments in constant glucose monitoring ( [33] ) in conjunction with the use of insulin pumps. A PID controller has been used to attempt to manage glucose with an artifical pancreas by [10, 11, 12, 13, 14, 15] , an approach which seems to be supported by this work.
It is interesting to note that when a PID controller has been used in an artifical pancreas in practice it caused glucose levels to drop too low, which meant that another attempt was made using just a PI controller (i.e. one with no differential term) however the differential term was determined well in the paper [34] . Defines the differential equations: Associated substitution rules are also defined to aid the symmetry package:
Independent and dependent variables are defined:
independentvariables={"t"}; independentvariables={"t"}; independentvariables={"t"};
dependentvariables={"x1","x2","x3","x4","p4","p5","p6", dependentvariables={"x1","x2","x3","x4","p4","p5","p6", dependentvariables={"x1","x2","x3","x4","p4","p5","p6", "p7" ,"p8","p9","p10","p11","p12"}; "p7" ,"p8","p9","p10","p11","p12"}; "p7" ,"p8","p9","p10","p11","p12"};
Package parameters are defined: The xse1=a10 + a12*z10 + a13*z11 + a14*z12 + a15*z13 + a16*z14 + a111*z6 + a112*z7 + a113*z8 + a114*z9 Glucose Effectiveness, insulin-independent glucose removal (most of the glucose removal in this test is determined by insulin hence the insensitivity)
Glucose production rate
Insulin sensitivity, insulin-dependent glucose removal
Proportional parameter for PID model
Integral parameter for PID model
Differential parameter for PID model
Insulin clearance
Integral clearance rate, to simulate integral function
Insulin action increase rate, to delay insulin action
Starting glucose
Starting insulin I a0 mmol l −1 min Starting insulin action (non-sensitive parameter)
I i0 µg l −1 min Starting insulin integral (non-sensitive parameter) 
